Establishing Best Practices for CML Therapy: A Workshop Symposium for the Advanced Practice Oncology Nurse
by Institute For Medical Education and Research (IMER) on May 14, 2012
- 1,058 views
In 2011, the treatment armamentarium dramatically expanded with the approval of the anti-CTLA4 antibody ipilimumab and the BRAF inhibitor vemurafenib. Oncology nurses who care for patients with ...
In 2011, the treatment armamentarium dramatically expanded with the approval of the anti-CTLA4 antibody ipilimumab and the BRAF inhibitor vemurafenib. Oncology nurses who care for patients with melanoma are beginning to administer these new agents and have numerous questions regarding their efficacy, different response patterns, unique toxicity profiles, how they may be integrated into current treatment regimens, and how to educate patients on their benefits and risks.
Downloadable slide decks are a great tool for self study and teaching purposes. They are non-certified resources available to enhance your knowledge.
Review a downloadable slide deck by Mollie E. Moran, MSN, CNP, AOCNP®, covering the most clinically relevant new data reported from Establishing Best Practices for CML Therapy: A Workshop Symposium for the Advanced Practice Oncology Nurse.
This activity has been designed to meet the educational needs of oncology advanced practitioners involved in the care of patients with chronic myelogenous leukemia (CML) who are interested in an advanced course on this topic.
Slide Deck Disclaimer
This slide deck in its original and unaltered format is for educational purposes and is current as of May 2012. All materials contained herein reflect the views of the faculty, and not those of IMER, the CE provider, or the commercial supporter. These materials may discuss therapeutic products that have not been approved by the US Food and Drug Administration and off-label uses of approved products. Readers should not rely on this information as a substitute for professional medical advice, diagnosis, or treatment. The use of any information provided is solely at your own risk, and readers should verify the prescribing information and all data before treating patients or employing any therapeutic products described in this educational activity.
For more information visit:
- Total Views
- Views on SlideShare
- Embed Views